• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Brooklyn ImmunoTherapeutics Inc. (Amendment)

    4/4/23 5:14:56 PM ET
    $BTX
    Get the next $BTX alert in real time by email
    SC 13G/A 1 d483934dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Eterna Therapeutics Inc.

    (Name of Issuer)

    Common stock, par value $0.005 per share

    (Title of Class of Securities)

    114082209

    (CUSIP Number)

    April 3, 2023

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐

    Rule 13d-1(b)

     

    ☒

    Rule 13d-1(c)

     

    ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


     

      1    

      Names of Reporting Persons.

      I.R.S. Identification Nos. of above persons (entities only)

     

      Freebird Partners LP

      2  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization.

     

      Texas

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5     

      Sole Voting Power

     

      0

       6   

      Shared Voting Power

     

      697,511(1)

       7   

      Sole Dispositive Power

     

      0

       8   

      Shared Dispositive Power

     

      697,511(1)

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      697,511(1)(2)

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11  

      Percent of Class Represented by Amount in Row (9)*

     

      12.6%(2)

    12  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    Includes (i) 272,583 shares of common stock, par value $0.005 per share (the “Common Stock”), of Eterna Therapeutics Inc., a Delaware corporation (the “Issuer”), and (ii) 424,928 shares of Common Stock of the Issuer (the “Warrant Shares”), issuable upon exercise of that certain Common Stock Purchase Warrant (the “Warrant”) issued by the Issuer in favor of Freebird Partners LP, a Texas limited partnership (“Freebird Partners”) which may be exercised at any time following June 2, 2023, at an exercise price of $3.28 per Warrant Share in substantially the form as the form of warrant filed as Exhibit 10.1 to the Issuer’s Current Report on Form 8-K filed with the SEC on December 5, 2022. Freebird Investments LLC, a Texas limited liability company (“Freebird Investments”), serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners.

    (2)

    Such percentage is based on an aggregate of 5,551,998 shares of Common Stock outstanding, which is calculated by adding (i) 5,127,070 shares of Common Stock issued and outstanding as of March 20, 2023 as reported in the Issuer’s Quarterly Report on Form 10-K filed with the SEC on March 20, 2023 and (ii) 424,928 Warrant Shares issuable upon exercise of the Warrant held by Freebird Partners sold pursuant to that certain Securities Purchase Agreement dated November 23, 2022 (the “Purchase Agreement”), as announced in the Issuer’s Current Report on Form 8-K filed with the SEC on November 25, 2022.


      1    

      Names of Reporting Persons.

      I.R.S. Identification Nos. of above persons (entities only)

     

      Freebird Investments LLC

      2  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization.

     

      Texas

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5     

      Sole Voting Power

     

      0

       6   

      Shared Voting Power

     

      697,511(1)

       7   

      Sole Dispositive Power

     

      0

       8   

      Shared Dispositive Power

     

      697,511(1)

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      697,511(1)(2)

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11  

      Percent of Class Represented by Amount in Row (9)*

     

      12.6%(1)(2)

    12  

      Type of Reporting Person (See Instructions)

     

      OO

     

    (1)

    Includes (i) 272,583 shares of Common Stock and (ii) 424,928 Warrant Shares of the Issuer issuable upon exercise of the Warrant directly beneficially owned by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Mr. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners.

    (2)

    Such percentage is based on an aggregate of 5,551,998 shares of Common Stock of the Issuer outstanding, which is calculated by adding (i) 5,127,070 shares of Common Stock issued and outstanding March 20, 2023 as reported in the Issuer’s Quarterly Report on Form 10-K filed with the SEC on March 20, 2023 and (ii) 424,928 Warrant Shares issuable upon exercise of the Warrant held by Freebird Partners, sold pursuant to the Purchase Agreement.


      1    

      Names of Reporting Persons.

      I.R.S. Identification Nos. of above persons (entities only)

     

      Curtis Huff

      2  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization.

     

      United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5     

      Sole Voting Power

     

      0

       6   

      Shared Voting Power

     

      697,511(1)

       7   

      Sole Dispositive Power

     

      0

       8   

      Shared Dispositive Power

     

      697,511(1)

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      697,511(1)(2)

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11  

      Percent of Class Represented by Amount in Row (9)*

     

      12.6%(1)(2)

    12  

      Type of Reporting Person (See Instructions)

     

      IN

     

    (1)

    Includes (i) 272,583 shares of Common Stock and (ii) 424,928 Warrant Shares of the Issuer issuable upon exercise of the Warrant directly beneficially owned by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Mr. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners.

    (2)

    Such percentage is based on an aggregate of 5,551,998 shares of Common Stock of the Issuer outstanding, which is calculated by adding (i) 5,127,070 shares of Common Stock issued and outstanding March 20, 2023 as reported in the Issuer’s Quarterly Report on Form 10-K filed with the SEC on March 20, 2023 and (ii) 424,928 Warrant Shares issuable upon exercise of the Warrant held by Freebird Partners sold pursuant to the Purchase Agreement.


    This Amendment No. 1 to Schedule 13G (this “Amendment”) amends and supplements the Schedule 13G filed by Freebird Partners LP with the Securities and Exchange Commission (the “Commission”) on December 2, 2022 (the “Schedule 13G”), relating to Common Stock of the Issuer to reflect the beneficial ownership of the Warrant Shares by the Reporting Persons (as defined below), because the Warrant is exercisable within 60 days of April 3, 2023.

    Item 1.

     

    (a)

    Name of Issuer

    Eterna Therapeutics Inc.

     

    (b)

    Address of Issuer’s Principal Executive Offices

    10355 Science Center Drive, Suite 150

    San Diego, CA 92121

    Item 2.

     

    (a)

    Name of Person Filing

    This statement is filed by the following entities and individuals (collectively, referred to as the “Reporting Persons”):

     

      •  

    Freebird Partners LP, a Texas limited partnership;

     

      •  

    Freebird Investments LLC, a Texas limited liability company;

     

      •  

    Curtis W. Huff, an individual and a citizen of the United States of America.

    Freebird Investments LLC is the general partner of Freebird Partners LP, and as a result, may be deemed to share voting and dispositive power with respect to the securities held by Freebird Partners LP.

    Curtis Huff is the sole member of Freebird Investments LLC, which is the general partner of Freebird Partners LP, and as a result, may be deemed to share voting and dispositive power with respect to the securities held by Freebird Partners LP.

    Freebird Partners LP, Freebird Investments LLC, and Mr. Huff have entered into a Joint Filing Agreement, a copy of which was filed with the Schedule 13G on December 2, 2022 as Exhibit 99.1, which is hereby incorporated by reference, pursuant to which they have agreed to file this Amendment jointly in accordance with the provisions of Rule 13d-1(k) of the Act.

     

    (b)

    Address of Principal Business Office or, if none, Residence

    The address of the principal business office for each of the Reporting Persons is:

    2800 Post Oak Blvd, Suite 2000

    Houston, TX 77056

     

    (c)

    Citizenship

    See Row 4 of cover page for each Reporting Person.

     

    (d)

    Title of Class of Securities

    Common stock, par value $0.005 per share.

     

    (e)

    CUSIP Number

    114082209


    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)

    Amount Beneficially Owned

    See Row 9 of cover page for each Reporting Person.

     

    (b)

    Percent of Class

    See Row 11 of cover page for each Reporting Person.

     

    (c)

    Number of shares as to which such person has:

     

    (i)

    sole power to vote or to direct the vote

    See Row 5 of cover page for each Reporting Person.

     

    (ii)

    shared power to vote or to direct the vote

    See Row 6 of cover page for each Reporting Person.

     

    (iii)

    sole power to dispose or to direct the disposition of

    See Row 7 of cover page for each Reporting Person.

     

    (iv)

    shared power to dispose or to direct the disposition of

    See Row 8 of cover page for each Reporting Person.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

    Item 6. Ownership of More than Five Percent on Behalf of another Person

    Not applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Not applicable.

    Item 8. Identification and Classification of Members of the Group

    Not applicable.

    Item 9. Notice of Dissolution of Group

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    April 4, 2023

    FREEBIRD PARTNERS LP

    By: Freebird Investments LLC, its general partner

     

    By:  

    /s/ Curtis Huff

    Name: Curtis Huff
    Title: Chairman and President

    FREEBIRD INVESTMENTS LLC

     

    By:  

    /s/ Curtis Huff

    Name: Curtis Huff
    Title: Chairman and President

    CURTIS HUFF

     

    By:  

    /s/ Curtis Huff

    Get the next $BTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BTX

    DatePrice TargetRatingAnalyst
    12/29/2021$9.00Overweight
    Cantor Fitzgerald
    10/6/2021$20.00Buy
    Maxim Group
    More analyst ratings

    $BTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

      Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: National Funds Ticker Distribution   Declaration- 5/1/2025 Ex-Date- 5/15/2025 Record- 5/15/2025 Payable- 6/2/2025   Ticker Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust* BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Quality Municipal Trust, Inc.* BKN $0.057000 - BlackRock Municipal Incom

      5/1/25 7:59:00 PM ET
      $BBN
      $BCAT
      $BCX
      $BDJ
      Finance Companies
      Finance
      Finance/Investors Services
      Trusts Except Educational Religious and Charitable
    • Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions

      Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capital

      4/30/25 7:40:00 PM ET
      $BBN
      $BCAT
      $BCX
      $BDJ
      Finance Companies
      Finance
      Finance/Investors Services
      Trusts Except Educational Religious and Charitable
    • BlackRock Announces Shareholder Approval of Strategy Changes to the BlackRock Technology and Private Equity Term Trust (BTX)

      BlackRock Advisors, LLC announced today the results of the Special Shareholder Meeting of the BlackRock Technology and Private Equity Term Trust (NYSE:BTX) (the "Trust"). Shareholders have approved (i) an amendment to the Trust's fundamental investment restriction with respect to industry concentration to allow the Trust to concentrate its investments in companies operating in one or more industries within the technology group of industries and (ii) a change in the Trust's diversification status under the Investment Company Act of 1940 from diversified to non-diversified. About BlackRock BlackRock's purpose is to help more and more people experience financial well-being. As a fiduciary to

      4/17/25 4:30:00 PM ET
      $BTX

    $BTX
    SEC Filings

    See more
    • SEC Form DEFA14A filed by BlackRock Technology and Private Equity Term Trust

      DEFA14A - BlackRock Technology & Private Equity Term Trust (0001836057) (Filer)

      3/28/25 2:46:10 PM ET
      $BTX
    • SEC Form N-CEN filed by BlackRock Technology and Private Equity Term Trust

      N-CEN - BlackRock Technology & Private Equity Term Trust (0001836057) (Filer)

      3/17/25 9:47:53 AM ET
      $BTX
    • SEC Form DEF 14A filed by BlackRock Technology and Private Equity Term Trust

      DEF 14A - BlackRock Technology & Private Equity Term Trust (0001836057) (Filer)

      3/12/25 4:33:33 PM ET
      $BTX

    $BTX
    Financials

    Live finance-specific insights

    See more
    • Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

      Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: National Funds Ticker Distribution   Declaration- 5/1/2025 Ex-Date- 5/15/2025 Record- 5/15/2025 Payable- 6/2/2025   Ticker Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust* BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Quality Municipal Trust, Inc.* BKN $0.057000 - BlackRock Municipal Incom

      5/1/25 7:59:00 PM ET
      $BBN
      $BCAT
      $BCX
      $BDJ
      Finance Companies
      Finance
      Finance/Investors Services
      Trusts Except Educational Religious and Charitable
    • Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions

      Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capital

      4/30/25 7:40:00 PM ET
      $BBN
      $BCAT
      $BCX
      $BDJ
      Finance Companies
      Finance
      Finance/Investors Services
      Trusts Except Educational Religious and Charitable
    • Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

      Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: National Funds Ticker Distribution   Declaration- 4/1/2025 Ex-Date- 4/15/2025 Record- 4/15/2025 Payable- 5/1/2025   Ticker Distribution Change From Prior Distribution   BlackRock Municipal Income Quality Trust*  BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Quality Municipal Trust, Inc.* BKN $0.057000 - BlackRock Municip

      4/1/25 6:55:00 PM ET
      $BBN
      $BCAT
      $BCX
      $BDJ
      Finance Companies
      Finance
      Finance/Investors Services
      Trusts Except Educational Religious and Charitable

    $BTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Brooklyn with a new price target

      Cantor Fitzgerald initiated coverage of Brooklyn with a rating of Overweight and set a new price target of $9.00

      12/29/21 7:03:49 AM ET
      $BTX
    • Maxim Group initiated coverage on Brooklyn ImmunoTherapeutics with a new price target

      Maxim Group initiated coverage of Brooklyn ImmunoTherapeutics with a rating of Buy and set a new price target of $20.00

      10/6/21 7:53:44 AM ET
      $BTX

    $BTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual Meeting

      SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn" or the "Company"), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Matt Angel, Ph.D., Co-Founder, Chairman, and CEO of Factor Bioscience Inc., as Interim Chief Executive Officer and President. He will replace Howard J. Federoff, M.D., Ph.D., Chief Executive Officer and President, who departs to focus on building a new venture. The Company also announces the appointment of Andrew Jackson as Chief

      5/31/22 7:30:00 AM ET
      $BTX
    • Amarin Announces Appointment of New Directors and Board Leadership Changes

      Erin Enright and Alfonso "Chito" Zulueta Appointed to Board of Directors New Board Members Bring Skills and Experience Aligned with the Company's Strategy Per Wold-Olsen Named Chairman of the Board David Stack and Joe Zakrzewski to Retire from the Board Actions Reflect Company and Board's Commitment to Ongoing Refreshment and Enhancement DUBLIN, Ireland and BRIDGEWATER, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced a series of appointments and leadership changes to its Board of Directors, including: Appointment of Erin Enright and Alfonso "Chito" Zulueta to the Board, effective immediately. Ms. Enright and Mr. Zulueta will sta

      5/19/22 8:23:13 AM ET
      $AMRN
      $BTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board of Directors

      NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces the appointment of two new members of the Company's Board of Directors. Erin S. Enright has served on multiple Boards of Directors, including within the medical and life sciences arenas, such as Keystone Dental (serving as Audit Committee Chair), Medical Facilities Corporation (serving as Audit and Investment Committee Chair), and Dynatronics Corporation (serving on the Audit, Compensati

      1/20/22 7:30:00 AM ET
      $BTX

    $BTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Cicala Peter

      3 - Eterna Therapeutics Inc. (0000748592) (Issuer)

      2/16/24 5:30:35 PM ET
      $BTX
    • SEC Form 4 filed by Luther Sanjeev

      4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

      1/3/24 5:02:56 PM ET
      $BTX
    • SEC Form 4 filed by Clarke Dorothy J

      4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

      1/3/24 5:01:31 PM ET
      $BTX

    $BTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Brooklyn ImmunoTherapeutics Inc. (Amendment)

      SC 13G/A - Eterna Therapeutics Inc. (0000748592) (Subject)

      1/31/24 7:05:56 AM ET
      $BTX
    • SEC Form SC 13G/A filed by Brooklyn ImmunoTherapeutics Inc. (Amendment)

      SC 13G/A - Eterna Therapeutics Inc. (0000748592) (Subject)

      1/19/24 10:31:54 AM ET
      $BTX
    • SEC Form SC 13D/A filed by Brooklyn ImmunoTherapeutics Inc. (Amendment)

      SC 13D/A - Eterna Therapeutics Inc. (0000748592) (Subject)

      12/22/23 12:05:20 PM ET
      $BTX